Search Results

, radiotherapy, and targeted therapy. The chemotherapeutic drugs used were vinorelbine, gemcitabine, UFUR (tegafur/uracil), CMF (cyclophosphamide, methotrexate, and fluorouracil), eribulin, capecitabine, and paclitaxel, and the endocrine drugs were goserelin

, luminal B, HER2-enriched, and basal-like, 15 which are associated with a different clinical course and sensitivity to chemotherapy. 16 Basal-like and HER2-enriched subgroups are associated with the highest rates of pCR to paclitaxel- and doxorubicin

guidelines, visit NCCN.org 4. Romond EH Jeong JH Rastogi P . Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab

distant disease) were treated with neoadjuvant chemotherapy (paclitaxel, ifosfamide, and cisplatin) and then surgical resection. They reported an objective response rate of 50%. “On the whole, this is far superior to what we see traditionally with surgery

a significant benefit in OS over gemcitabine monotherapy, until recently. In 2011 and 2013, progress was made with the publication of the PRODIGE 4/ACCORD 11 4 and MPACT 5 studies, showing survival benefits for FOLFIRINOX and gemcitabine/nab-paclitaxel

have suggested that KANK1 , a tumor suppressor gene, can mediate paclitaxel resistance in lung adenocarcinoma A549 cells. In addition, a previous study also reported a pancreatic neuroendocrine carcinoma patient with a KANK1::ALK fusion who exhibited

doublet regimen with a significant improvement in OS, paved the way for SWOG 1815, which compared gemcitabine, cisplatin, and nab-paclitaxel with gemcitabine + cisplatin. Although there was a numerical improvement in PFS, OS, and response rates among the

chemotherapy as a first-line treatment of PD-L1–positive TNBC. The study compared pertuzumab and chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin) with chemotherapy alone in patients who had not received prior treatment of metastatic disease

, paclitaxel, or vinflunine). 2 Key findings from the study included an improved overall response rate (ORR) with enfortumab vedotin (40.6%) compared with standard chemotherapy (17.9%). Complete response rates were also increased with enfortumab vedotin (4

chemoradiation with carboplatin and paclitaxel was also well-tolerated, resulting in superior overall and disease-specific survivals compared with cisplatin and irinotecan in patients with locally advanced esophageal cancer. 136 In a retrospective study